Endocannabinoid System and Chronic Low Back Pain: A Phase 3 Trial on Cannabis Sativa Extracts
Clinical Takeaway In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up reaching 15 months total. The trial design included both a…
Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.
Melanoma is a malignant neoplasm that originates from melanocytes. It continues to pose a significant challenge in oncology due to its aggressive nature and ...
Cannabis Extract Linked to Pain Reduction in Uncontrolled German Study, But Design Limits Conclusions
Despite observed reductions in pain intensity and improvements in quality of life, the single-arm design means that placebo effects, regression to the mean, and natural disease fluctuation cannot be excluded as explanations for the findings.
Cannabis Extract Linked to Pain Reduction in Small Observational Study—But Proof of Causation Is Absent
Mean NRS-assessed pain intensity decreased during the study, in both the ITT (5.46 ± 1.73 at V1 vs. 3.37 ± 2.43 at V4) and in the cannabis-naïve subgroup (5.92 ± 1.34 at V1 vs. 2.37 ± 1.69 at V4).
Experimental cannabis extract can help reduce chronic back pain, trial finds – MSN
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Chronic PainBack PainClinical TrialsPain…